{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:09:23Z","timestamp":1785337763528,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Teriparatide (TPTD), a widely used bone-promoting drug in osteoporosis (OP) treatment, may cause compensatory bone resorption with long-term monotherapy (&amp;gt;6\u00a0months). Combining TPTD with anti-bone resorption drugs (e.g., bisphosphonates and denosumab) could reduce bone loss, yet existing randomised controlled trials (RCTs) remain inconclusive regarding their effects on bone mineral density (BMD) and bone turnover markers (BTMs). This study aimed to systematically evaluate the effect of TPTD combined with bisphosphonates or denosumab on BMD and fracture risk in OP patients, compared with TPTD monotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, Cochrane Library, and Web of Science databases (until March 2025) were searched for RCTs comparing TPTD monotherapy with combination therapy. Primary outcomes included vertebral\/non-vertebral fracture risk reduction and BMD changes (lumbar spine, femoral neck, hip); secondary outcomes covered BTM variations and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight RCTs (n = 787) were meta-analysed using Review Manager 5.4. Results showed: \u2460 No significant differences in vertebral (OR = 0.93, 95%CI 0.12\u20136.93) or non-vertebral fractures (OR = 0.68, 0.31\u20131.46) between groups. \u2461 TPTD combined with denosumab significantly increased lumbar spine (+3.40%, 0.44\u20136.36), femoral neck (+4.00%, 1.96\u20136.04), and hip BMD (+4.25%, 3.20\u20135.29). Bisphosphonate combinations improved hip BMD in the short term (&amp;lt;24\u00a0months: +1.81%, 0.65\u20132.97) but not long-term (\u226524 months).\u2462 Combination therapies regulated BTMs bidirectionally: bisphosphonates suppressed P1NP (40%\u201380% reduction vs. monotherapy), while denosumab preserved OC levels (-8\u201316% vs. monotherapy).\u2463 Safety profiles were comparable: hypercalcemia incidence (16.3% vs. 14.7%, OR = 1.22, 0.55\u20132.69), musculoskeletal pain (9.8% overall), with no osteonecrosis cases reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TPTD-denosumab combination is clinically preferable for BMD enhancement, though its long-term (&amp;gt;24\u00a0months) fracture risk reduction requires further validation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1605279","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:25:29Z","timestamp":1747805129000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy of teriparatide and bisphosphonates or denosumab vs. teriparatide monotherapy in osteoporosis: a meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Huan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/14656566.2020.1717468","article-title":"Combination and sequential treatment in women with postmenopausal osteoporosis","volume":"21","author":"Anastasilakis","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"ii27","DOI":"10.1093\/ageing\/afl081","article-title":"The role of cortical bone and its microstructure in bone strength","volume":"35","author":"Augat","year":"2006","journal-title":"Age Ageing"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.3390\/jcm10133002","article-title":"The treatment gap in osteoporosis","volume":"10","author":"Ayub","year":"2021","journal-title":"J. Clin. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/ijms23031376","article-title":"Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover","volume":"23","author":"Cheng","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/bonekey.2014.13","article-title":"Combination therapy for osteoporosis: a reappraisal","volume":"3","author":"Cosman","year":"2014","journal-title":"Bonekey Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Min. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1040638716679861","article-title":"Mechanisms of bone response to injury","volume":"29","author":"Dittmer","year":"2017","journal-title":"J. Vet. Diagn Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1210\/jc.2009-0154","article-title":"Effects of teriparatide retreatment in osteoporotic men and women","volume":"94","author":"Finkelstein","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.eprac.2021.05.012","article-title":"Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis","volume":"27","author":"Kocjan","year":"2021","journal-title":"Endocr. Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1359\/jbmr.2002.17.9.1667","article-title":"Cyclic adenosine monophosphate\/protein kinase A mediates parathyroid hormone\/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells","volume":"17","author":"Kondo","year":"2002","journal-title":"J. Bone Min. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","article-title":"Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies","volume":"116","author":"Langdahl","year":"2018","journal-title":"Bone"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jbmr.1919","article-title":"Fast trabecular bone strength predictions of HR-pQCT and individual trabeculae segmentation-based plate and rod finite element model discriminate postmenopausal vertebral fractures","volume":"28","author":"Liu","year":"2013","journal-title":"J. Bone Min. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/BOR.0000000000000885","article-title":"Osteoporosis epidemiology using international cohorts","volume":"34","author":"Lorentzon","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/jbmr.4632","article-title":"Identifying causes of fracture beyond bone mineral density: evidence from human genetics","volume":"37","author":"Lu","year":"2022","journal-title":"J. Bone Min. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","article-title":"Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update","volume":"195","author":"Morin","year":"2023","journal-title":"CMAJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/jbmr.1716","article-title":"Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density","volume":"28","author":"Muschitz","year":"2013","journal-title":"J. Bone Min. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/jbmr.2216","article-title":"Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density-the CONFORS Study","volume":"29","author":"Muschitz","year":"2014","journal-title":"J. Bone Min. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"0108021","DOI":"10.1115\/1.4029176","article-title":"Biomechanics and mechanobiology of trabecular bone: a review","volume":"137","author":"Oftadeh","year":"2015","journal-title":"J. Biomech. Eng."},{"key":"B30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2213-8587(18)30308-5","article-title":"Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study","volume":"7","author":"Samelson","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1528","DOI":"10.1210\/clinem\/dgab850","article-title":"Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis","volume":"107","author":"Shane","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ecl.2016.09.008","article-title":"Combined pharmacologic therapy in postmenopausal osteoporosis","volume":"46","author":"Shen","year":"2017","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s11999-010-1722-9","article-title":"Anabolic agents and bone quality","volume":"469","author":"Sibai","year":"2011","journal-title":"Clin. Orthop. Relat. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ecl.2016.09.005","article-title":"Trabecular bone score: a new DXA-derived measurement for fracture risk assessment","volume":"46","author":"Silva","year":"2017","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"B36","first-page":"3","article-title":"Uses and limitations of bone mineral density measurements in the management of osteoporosis","volume":"7","author":"Small","year":"2005","journal-title":"MedGenMed"},{"key":"B37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","article-title":"International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis","volume":"49","author":"Vasikaran","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00198-022-06454-3","article-title":"Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis","volume":"33","author":"Xiao","year":"2022","journal-title":"Osteoporos. Int."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","article-title":"Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis","volume":"66","author":"Yuan","year":"2019","journal-title":"Int. J. Surg."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1605279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:25:29Z","timestamp":1747805129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1605279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":41,"alternative-id":["10.3389\/fphar.2025.1605279"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1605279","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1605279"}}